Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HMPL-453 + docetaxel
- Development stage
- Phase 2
- Lead developer
- HUTCHMED
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
HMPL-453 + docetaxel is a combination therapy under investigation for advanced solid tumors, comprising HMPL-453—a novel, highly selective, and potent small molecule inhibitor targeting fibroblast growth factor receptors FGFR1, FGFR2, and FGFR3—and docetaxel, a taxane-class chemotherapy. HMPL-453 inhibits the FGFR pathway, which is implicated in tumor growth, angiogenesis, and therapy resistance, while docetaxel disrupts microtubule dynamics, inhibiting cell division. This combination targets tumors with aberrant FGFR signaling and is being assessed for safety, tolerability, pharmacokinetics, and preliminary efficacy, particularly in patients with advanced solid tumors refractory to standard treatments[2][6].
- Other names
- HMPL-453HMPL453HMPL 453fanregratinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on HMPL-453 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HMPL-453 + docetaxel.